CA3084298A1 - Agents antifongiques derives de pyridine substitues par un heterocycle - Google Patents

Agents antifongiques derives de pyridine substitues par un heterocycle Download PDF

Info

Publication number
CA3084298A1
CA3084298A1 CA3084298A CA3084298A CA3084298A1 CA 3084298 A1 CA3084298 A1 CA 3084298A1 CA 3084298 A CA3084298 A CA 3084298A CA 3084298 A CA3084298 A CA 3084298A CA 3084298 A1 CA3084298 A1 CA 3084298A1
Authority
CA
Canada
Prior art keywords
compound
stereoisomer
solvate
tautomer
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3084298A
Other languages
English (en)
Inventor
Michael Trzoss
Jonathan COVEL
Karen Joy Shaw
Peter Webb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Basilea Pharmaceutica International Ag Allschwil
Original Assignee
Amplyx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amplyx Pharmaceuticals Inc filed Critical Amplyx Pharmaceuticals Inc
Publication of CA3084298A1 publication Critical patent/CA3084298A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des agents antifongiques dérivés de pyridine substitués par un hétérocycle et des compositions pharmaceutiques comprenant lesdits composés. Les composés et compositions de l'invention sont utiles pour le traitement de maladies et d'infections fongiques.
CA3084298A 2017-12-07 2018-12-07 Agents antifongiques derives de pyridine substitues par un heterocycle Pending CA3084298A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762595894P 2017-12-07 2017-12-07
US62/595,894 2017-12-07
US201862649225P 2018-03-28 2018-03-28
US62/649,225 2018-03-28
PCT/US2018/064609 WO2019113542A1 (fr) 2017-12-07 2018-12-07 Agents antifongiques dérivés de pyridine substitués par un hétérocycle

Publications (1)

Publication Number Publication Date
CA3084298A1 true CA3084298A1 (fr) 2019-06-13

Family

ID=66751743

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084298A Pending CA3084298A1 (fr) 2017-12-07 2018-12-07 Agents antifongiques derives de pyridine substitues par un heterocycle

Country Status (19)

Country Link
US (2) US11512079B2 (fr)
EP (1) EP3720438B1 (fr)
JP (2) JP7292299B2 (fr)
KR (1) KR20200096941A (fr)
CN (1) CN111698989B (fr)
AU (1) AU2018379077B2 (fr)
BR (1) BR112020011162A2 (fr)
CA (1) CA3084298A1 (fr)
DK (1) DK3720438T3 (fr)
ES (1) ES2962986T3 (fr)
FI (1) FI3720438T3 (fr)
HU (1) HUE065201T2 (fr)
IL (1) IL275121A (fr)
MA (1) MA51052A (fr)
MX (1) MX2020005927A (fr)
PL (1) PL3720438T3 (fr)
PT (1) PT3720438T (fr)
WO (1) WO2019113542A1 (fr)
ZA (1) ZA202003281B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3720438T3 (da) * 2017-12-07 2023-10-02 Amplyx Pharmaceuticals Inc Svampedræbende midler, der er afledt af heterocyklus-substitueret pyridin
AU2019294474A1 (en) 2018-06-25 2021-02-11 Basilea Pharmaceutica International Ag, Allschwil Pyridine derivatives substituted by heterocyclic ring and amino group
WO2020247804A1 (fr) * 2019-06-07 2020-12-10 Amplyx Pharmaceuticals, Inc. Agents antifongiques dérivés de pyridine substitués par un hétérocycle
KR20220148881A (ko) * 2020-03-04 2022-11-07 앰플릭스 파마슈티컬스, 인크. 진균 감염 치료에서의 화합물의 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
DK1373263T3 (da) 2001-04-05 2005-03-07 Torrent Pharmaceuticals Ltd Heterocycliske forbindelser til aldringsrelaterede og diabetesbetingede vaskulære sygdomme
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
AU2006309762B2 (en) * 2005-10-31 2010-02-25 Eisai R&D Management Co., Ltd. Heterocyclic substituted pyridine derivatives and antifungal agent containing same
CN101426766B (zh) * 2006-04-19 2014-03-26 默克雪兰诺有限公司 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
DE102006020327A1 (de) * 2006-04-27 2007-12-27 Bayer Healthcare Ag Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
KR20100015897A (ko) 2007-04-27 2010-02-12 에자이 알앤드디 매니지먼트 가부시키가이샤 헤테로환 치환 피리딘 유도체의 염 또는 그의 결정
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
WO2009055042A1 (fr) * 2007-10-24 2009-04-30 Amplyx Pharmaceuticals, Inc. Amélioration de l'efficacité de produits thérapeutiques anti-infectieux
WO2009081970A1 (fr) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Procédé pour la fabrication d'un dérivé de pyridine substitué par un hétérocycle
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20110201649A1 (en) * 2008-09-19 2011-08-18 Sumitomo Chemical Company, Limited agricultural composition
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
JP2012176900A (ja) 2009-06-24 2012-09-13 Eisai R & D Management Co Ltd （（ホスホノオキシ）メチル）ピリジニウム環を有するピリジン誘導体およびそれらを含有する抗真菌剤
WO2011051198A2 (fr) * 2009-10-30 2011-05-05 Bayer Cropscience Ag Dérivés de pyridine en tant qu'agents phytoprotecteurs
DK3720438T3 (da) 2017-12-07 2023-10-02 Amplyx Pharmaceuticals Inc Svampedræbende midler, der er afledt af heterocyklus-substitueret pyridin
AU2019294474A1 (en) * 2018-06-25 2021-02-11 Basilea Pharmaceutica International Ag, Allschwil Pyridine derivatives substituted by heterocyclic ring and amino group
WO2020247804A1 (fr) 2019-06-07 2020-12-10 Amplyx Pharmaceuticals, Inc. Agents antifongiques dérivés de pyridine substitués par un hétérocycle

Also Published As

Publication number Publication date
MA51052A (fr) 2021-04-21
JP2021505672A (ja) 2021-02-18
ES2962986T3 (es) 2024-03-22
AU2018379077B2 (en) 2023-04-27
HUE065201T2 (hu) 2024-05-28
DK3720438T3 (da) 2023-10-02
JP7292299B2 (ja) 2023-06-16
JP2023113800A (ja) 2023-08-16
FI3720438T3 (fi) 2023-09-01
CN111698989B (zh) 2023-08-01
AU2018379077A1 (en) 2020-06-25
EP3720438B1 (fr) 2023-08-30
BR112020011162A2 (pt) 2020-11-17
US11512079B2 (en) 2022-11-29
WO2019113542A1 (fr) 2019-06-13
EP3720438A4 (fr) 2021-06-16
US20210163461A1 (en) 2021-06-03
KR20200096941A (ko) 2020-08-14
US20230065881A1 (en) 2023-03-02
MX2020005927A (es) 2020-10-07
PL3720438T3 (pl) 2024-03-18
ZA202003281B (en) 2023-10-25
PT3720438T (pt) 2023-12-07
CN111698989A (zh) 2020-09-22
EP3720438A1 (fr) 2020-10-14
IL275121A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
US10626095B2 (en) Cyanotriazole compounds
CA3084298A1 (fr) Agents antifongiques derives de pyridine substitues par un heterocycle
US11014881B2 (en) Hepatitis B capsid assembly modulators
CN105492437B (zh) 取代的苯并呋喃基和苯并噁唑基化合物及其用途
AU2014241183B2 (en) 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide derivatives and their use as PHD inhibitors
US9180192B2 (en) mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
AU2013332648B2 (en) Sodium channel blockers, preparation method thereof and use thereof
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
AU2010275477A1 (en) Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators
WO2020247804A1 (fr) Agents antifongiques dérivés de pyridine substitués par un hétérocycle
EP3883573B1 (fr) Inhibiteurs macrocycliques de dyrk1a
JP2015526411A (ja) 窒素複素環誘導体及びその医薬品への応用
JP2012527475A (ja) 尿酸値を調節するための化合物、組成物及び方法
CN108473478A (zh) TBK/IKKε抑制剂化合物及其用途
CA2793311A1 (fr) Modulateurs de l'activite hec1 et procedes associes
TW201302730A (zh) 吡唑化合物
WO2019190885A1 (fr) Modulateurs de calpaïne et leurs utilisations thérapeutiques
JP2018538357A (ja) 化合物
JP6883045B2 (ja) オレキシン受容体調節因子としてのハロ置換ピペリジン
WO2015134171A1 (fr) Inhibiteurs hétéroarylamide de tbk1
US11884627B2 (en) Compounds and compositions for treating conditions associated with LPA receptor activity
CN106279138B (zh) 芳杂环类衍生物及其在药物中的应用
OA19832A (en) Heterocycle substituted pyridine derivative antifungal agents.
CN108997328A (zh) 亚氨基噻二嗪二氧化物衍生物及其用途
WO2024112895A1 (fr) Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa